within Pharmacolibrary.Drugs.ATC.L;

model L01XH03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.21,
    Cl             = 0.5583333333333333,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.382,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013666666666666666,
    Tlag           = 11.4
  );

  annotation(Documentation(
    info ="<html><body><p>Panobinostat is a potent pan-deacetylase inhibitor approved for the treatment of multiple myeloma, typically used in combination with other agents in patients who have received prior treatments. It is administered orally and acts by inhibiting histone deacetylases, thereby inducing apoptosis and cell cycle arrest in malignant cells.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients with advanced hematologic malignancies after oral administration.</p><h4>References</h4><ol><li>Mathilde Van Veggel, Elsbeth Westerman, Paul Hamberg,Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.,Clinical pharmacokinetics,2018<a href='https://pubmed.ncbi.nlm.nih.gov/28667459/'>https://pubmed.ncbi.nlm.nih.gov/28667459/</a></li><li>Nuggehally R Srinivas,Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives.,Xenobiotica; the fate of foreign compounds in biological systems,2017<a href='https://pubmed.ncbi.nlm.nih.gov/27226420/'>https://pubmed.ncbi.nlm.nih.gov/27226420/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XH03;
